plerixafor stem cell
Selected indexed studies
- Plerixafor for stem cell mobilization: the current status. (Curr Opin Hematol, 2016) [PMID:26554889]
- Hematopoietic stem cell mobilization with plerixafor in sickle cell disease. (Haematologica, 2018) [PMID:29712818]
- Addition of plerixafor in poorly mobilized allogeneic stem cell donors. (J Clin Apher, 2022) [PMID:35633513]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Plerixafor for stem cell mobilization: the current status. (2016) pubmed
- Hematopoietic stem cell mobilization with plerixafor in sickle cell disease. (2018) pubmed
- Addition of plerixafor in poorly mobilized allogeneic stem cell donors. (2022) pubmed
- Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. (2016) pubmed
- [Research Progress on the Application Strategies of Plerixafor in the Peripheral Blood Stem Cell Mobilization for Autologous Transplantation--Review]. (2024) pubmed
- UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. (2018) pubmed
- Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience. (2021) pubmed
- Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. (2010) pubmed
- Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide. (2019) pubmed
- Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. (2021) pubmed